Treatment of Atopic Dermatitis Using JAK Inhibitors: A Systematic Review
Background: The advent of JAK inhibitors (JAKi) has significantly modernised the treatment of atopic dermatitis (AD), offering a novel approach to treating this recalcitrant dermatological condition. Although topical treatment is shown to be effective, oral formulations are yet to be widely utilised...
Saved in:
Main Authors: | Stefan Siedlikowski (Author), Vijay Sandhu (Author), Charles Lynde (Author) |
---|---|
Format: | Book |
Published: |
European Medical Journal,
2019-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors
by: Mark G. Kirchhof, et al.
Published: (2024) -
Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020) -
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
by: Helena Iznardo, et al.
Published: (2023) -
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
by: Masahiro Kamata, et al.
Published: (2023) -
Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients
by: Tiago Torres, et al.
Published: (2021)